Is BNGO up or down today?
BNGO is up 1.67% today, last at 1.22. This stock moved +1.67% versus the prior close.
BNGO · BNGO
BNGO (BNGO) is trading at 1.22, up 1.67% on the session. BNGO sits at the 5% mark of its 52-week range, carries a 14-day RSI of 54, and trades above its 50-day average. Over the past month it is up 1.67%.
Leading the coverage: “Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping” (Yahoo, 4d ago). BNGO is +1.67% since story.
BNGO trades on a trailing P/E of 20.1 and is running 2.73% ahead of the S&P 500 over the same stretch.
Analyst firms are mostly reiterating — no strong directional shift lately.
BNGO is up 1.67% today, last at 1.22. This stock moved +1.67% versus the prior close.
Leading the coverage: “Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping” (Yahoo, 4d ago). BNGO is +1.67% since story. Dominant story: Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms (2 sources, neutral) RSI is 54 — neutral Price above 50-day average — short-term uptrend Social sentiment loads separately — see the Social tab.
Analyst firms are mostly reiterating — no strong directional shift lately.
Loaded: Mar 2026 – Sep 2026 (125 days) · Drag or scroll left for earlier dates
Bionano Laboratories Announces Proposed Local Coverage Determination (LCD) from MolDX for Genome-Wide Detection of Structural Variants in Hematologic Neoplasms
Bionano Genomics Subsidiary Says MolDX Issues Proposed LCD For Genome-Wide Molecular Methodologies For Detection Of Copy Number Alterations And Structural Variants In Hematologic Neoplasms
MolDX proposes Medicare coverage for Bionano genome mapping test By Investing.com - Investing.com Nigeria
Bionano Genomics (BNGO) interim CEO adds 4,000 shares in IRA - Stock Titan
Bionano Laboratories Announces New York State Department of Health Approval of Lab Developed Tests Based on Optical Genome Mapping